1617 ZhJ



CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 26, 2004

Date

Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING

ANTIBODIES TO

AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A non-final Official Action on the merits has been received in the present application.

However, this Supplemental Information Disclosure Statement is being filed prior to the mailing

of a final Official Action, notice of allowance or an Action that closes prosecution, and is timely

filed in accordance with 37 C.F.R. § 1.97(c) without a fee in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the document listed

on the accompanying Form PTO-1449 was not cited in a communication from a foreign patent

office in a counterpart foreign application. The listed document was cited in an Official Action

on the merits in a co-pending application of one of the present inventors, Serial No. 09/998,833

(Attorney Docket No. 4001.002299), mailed from the P.T.O. on September 08, 2004, less than

three months before the filing of the present statement, and could not have been submitted before

receipt.

No fees are due in connection with the filing of this Supplemental Information Disclosure

Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for

any reason, the Examiner should contact the undersigned representative to discuss deduction

from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,

Williams, Morgan & Amerson, P.C.

Customer No. 23720

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Agent for Applicants

10333 Richmond, Suite 1100 Houston, Texas, 77042

(713) 934-4079

Date: October 26, 2004

2

MATION (Use sev Patent I See Po		ATEMENT y) Foreign F	4001.0 Applic Thorp Filing July 12 Patent Do	ant e and Ran Date: 2, 1999 ocuments	09/	rial No. /351,862 oup: 17 Other A See Page	
MATION (Use sev Patent I See Pa	N DISCLOSURE ST veral sheets if necessar Documents age	ATEMENT y) Foreign F	Filing July 12 Patent Do See Page	Date: 2, 1999 ocuments		0ther A	
(Use sev Patent I See Po	veral sheets if necessar Documents age	y) Foreign F	July 12 Patent Do See Page	cuments		0ther A	
See Po	age		See Page				
		U.S. Pate	nt Do				
	Decument		00	cuments			
es.	Document Number	Date		Name	Class	Sub Class	Filing Date of App.
	F	oreign Pa	tent D	ocuments			
Ref. Des.	Document Number	Da	ate	Country	Class	Sub Class	Translation Yes/No
her A	rt (Includin	g Author,	Title,	Date Perti	nent P	ages, l	Etc.)
Ref. Des.	Citation						
119							
h	ner A	Ref. Document Number ner Art (Including Ref. Des. 19 Tschmelitsch et al Labeled Monoclon	Ref. Document Number Des. Number Des. Number Des. Des. Des. Des. Des. Des. Des. Des.	Ref. Document Number Date ner Art (Including Author, Title, Ref. Des. 19 Tschmelitsch et al., "Enhanced Antitumor Labeled Monoclonal Antibody A33) with containing the second	Ref. Document Number Date Country Ther Art (Including Author, Title, Date Perticular) Ref. Citation Technelitsch et al., "Enhanced Antitumor Activity of Combabeled Monoclonal Antibody A33) with chemotherapy (Fl	ner Art (Including Author, Title, Date Pertinent P Ref. Des. Tschmelitsch et al., "Enhanced Antitumor Activity of Combination Ra Labeled Monoclonal Antibody A33) with chemotherapy (Fluorouracil)	Ref. Document Number Date Country Class Sub Class Ter Art (Including Author, Title, Date Pertinent Pages, Including Author, Title, Date Pertinent Pages, Including Citation Ter Art (Including Author, Title, Date Pertinent Pages, Including Citation Technelitsch et al., "Enhanced Antitumor Activity of Combination Radioimmun Labeled Monoclonal Antibody A33) with chemotherapy (Fluorouracil)," Cancer

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form I	TO 144										
Form PTO-1449 (modified)				1 -	Atty. Docket No.			Serial No.			
Link of Potents and Publications for Annliant's				4001.002282 09/351,862							
List of Patents and Publications for Applicant's					Applicant Thorpe and Ran						
\در. العزالية	ORMATIO	ON DISCLOSURE STA	ATEMENT	1 1101	i pe a	nu Kan					
2004	2004 INFORMATION DISCLOSURE STATEMENT			Filin	Filing Date:				Group:		
NE T	(Use :	several sheets if necessary)	July	12, 1	999		161	-		
ADEAR U		Documents	Foreign l			ments			Other A		
	See	Page	-	See Pag	ge		·		See Page	e I	
			U.S. Pate	nt Do	oci	ıments				<u> </u>	
Exam. Init.	m. Ref. Document		Date			Name	Class		Sub Class	Filing Date of App.	
		Fo	reign Pa	tent	Do	cuments	•				
Exam. Init.	Ref. Des.	Document Number	Di	te Country Cla			Clas	ss	Sub Class	Translation Yes/No	
mi.	Des.	111111111111111111111111111111111111111					+		i		
mit.	Des.										
		Art (Including	Author,	Title	e, D	ate Perti	inen	t Pa	ages,	Etc.)	
			g Author,	Title		ate Perti	inen	t Pa	ages,	Etc.)	
Exam.	Other Ref.		stein, "The Er	ndotheli	Ci um a	tation nd Red Blood	d Cell				
Exam.	Other Ref. Des.	Art (Including	stein, "The Er tasis," <i>J. Radi</i>	ndothelii at. Biol.	Ci um a ., 60(tation nd Red Blood 1/2):293-301,	d Cell 1991.	as Po	otential T		
Exam.	Other Ref. Des.	Art (Including Ben-Hur and Orens Induced Vascular S	stein, "The Er tasis," <i>J. Radi</i> Angiogenesis, The Discovery	ndothelin at. Biol. " Adv. C	Cirum a	nd Red Blood 1/2):293-301, er Res., 43:17:	d Cell 1991. 5-203,	as Po	otential T	argets in PDT-	
Exam.	Other Ref. Des. C111	Ben-Hur and Orens Induced Vascular S Folkman, "Tumor Gschwind et al., "T	stein, "The Er tasis," J. Radi Angiogenesis, The Discovery ncer, 4:361-37	ndothelin at. Biol. " Adv. Co of Rece 70, 2004 EGF-Me	um a ., 60(Cance eptor	nd Red Blood 1/2):293-301, er Res., 43:175 Tyrosine Kin	d Cell 1991. 5-203,	as Po	otential T . ets for Ca	argets in PDT-	
Exam.	Other Ref. Des. C111 C112 C113	Ben-Hur and Orens Induced Vascular S Folkman, "Tumor and Gschwind et al., "To Nature Reviews/Caste Martiny-Baron and	stein, "The Eratasis," J. Radio Angiogenesis, The Discovery Incer, 4:361-37 Marmé, "Vicurr. Opin. Bio Juk, "Signification	ndothelinat. Biol. " Adv. Cof Rece 70, 2004 EGF-Motech., 6	cium a., 60(Cance eptor 1.	nd Red Blood 1/2):293-301, er Res., 43:17: Tyrosine Kin ed Tumour A -680, 1995.	d Cell 1991. 5-203, nases:	as Po 1985 Targo enesi	otential T . ets for Ca	argets in PDT- ncer Therapy,'	
Exam.	Other Ref. Des. C111 C112 C113	Ben-Hur and Orens Induced Vascular S Folkman, "Tumor Gschwind et al., "Town Nature Reviews/Cale Martiny-Baron and Cancer Therapy," Company of McDonald and Bale Service (Service) (Service	stein, "The Er tasis," J. Radio Angiogenesis, The Discovery Incer, 4:361-37 Marmé, "Vi Curr. Opin. Bio uk, "Significan 2.	ndothelinat. Biol. " Adv. Cof Rece 70, 2004 EGF-Motech., 6 nce of E	um a ., 60(Cance eptor 1. dediate 5:675- Blood	nd Red Blood 1/2):293-301, er Res., 43:17: Tyrosine Kin ed Tumour A -680, 1995. d Vessel Leak	d Cell 1991. 5-203, nases: Angiog	as Po	ets for Ca	argets in PDT ncer Therapy,' ew Target for ncer Research	
Exam.	C111 C112 C113 C114 C115	Ben-Hur and Orens Induced Vascular S Folkman, "Tumor Gschwind et al., "Town Martiny-Baron and Cancer Therapy," Company of McDonald and Ball 62:5381-5385, 2002 Murata et al., "Imm	stein, "The Ertasis," J. Radio Angiogenesis, The Discovery Incer, 4:361-37 Marmé, "Vicurr. Opin. Bio Juk, "Significand Language Control of the Control of th	ndothelinat. Biol. " Adv. Cof Recee 70, 2004 EGF-Mentech., 6 nice of E	um a., 60(Cance eptor 1. fediate 5:675- Blood etection	nd Red Blood 1/2):293-301, er Res., 43:173 Tyrosine Kin ed Tumour A-680, 1995. I Vessel Leak on of Extrava	d Cell 1991. 5-203, nases: Angiogo iness in sated F	as Po 1985 Targe enesi n Car Fibrin 31, 1	otential T ets for Ca is: A N ncer," Ca	argets in PDT- ncer Therapy,' ew Target for ncer Research	

EXAMINER:		DATE CONSIDERED:	

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.